Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease ; volume:69 ; number:6 ; day:18 ; month:4 ; year:2024 ; pages:2175-2183 ; date:6.2024
Digestive diseases and sciences ; 69, Heft 6 (18.4.2024), 2175-2183, 6.2024
- Creator
-
Lamichhane, N.
Melas, N.
Bergqvist, V.
Ekholm, N.-P
Olén, O.
Ludvigsson, J. F.
Hjortswang, H.
Marsal, J.
Eriksson, C.
Halfvarson, J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10620-024-08422-9
- URN
-
urn:nbn:de:101:1-2408161033057.730578429611
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lamichhane, N.
- Melas, N.
- Bergqvist, V.
- Ekholm, N.-P
- Olén, O.
- Ludvigsson, J. F.
- Hjortswang, H.
- Marsal, J.
- Eriksson, C.
- Halfvarson, J.
- SpringerLink (Online service)
Other Objects (12)
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
China's transitioning class identity
Transient Small Bowel Angio-oedema Secondary to Intravenous Iodinated Contrast Medium
Transient angioedema of small bowel secondary to intravenous iodinated contrast medium
Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
China's transitioning class identity
Transient Small Bowel Angio-oedema Secondary to Intravenous Iodinated Contrast Medium
Transient angioedema of small bowel secondary to intravenous iodinated contrast medium
Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization
Inflammatory Bowel Disease Patients’ Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration
Elemental mercury poisoning caused by subcutaneous and intravenous injection: An unusual self-injury
Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
China's transitioning class identity
Transient Small Bowel Angio-oedema Secondary to Intravenous Iodinated Contrast Medium
Transient angioedema of small bowel secondary to intravenous iodinated contrast medium